Clinical Trials

500 enrolled

Phase 2/3 Not yet recruiting

Non Squamous Non-small Cell Lung Cancer

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

159 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05570422 2025-09-11

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

70 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07151872 2025-09-03

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

120 enrolled

Gastrointestinal

CLDN18.2-positive Advanced Biliary Tract Cancer

NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

60 enrolled

CNS

Glioblastoma

NCT06970782 2025-05-21

KYLIN-3

278 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

762 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

380 enrolled

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

350 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06446388 2024-06-06

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

360 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

398 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05767892 2023-04-05

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)